Skip to main content

Table 4 Appraisal of the patient decision aid (n = 69)

From: Evaluation of a patient decision aid for initiating disease modifying anti-rheumatic drugs

 

Mostly disagree

(1 point)

Neutral

(3 points)

Mostly agree

(5 points)

Mean ± SD

Subjective impact of the PtDA

 I learned a lot from the PtDA

11 %

17 %

71 %

 

 The PtDA contained new information

7 %

23 %

70 %

 

 The PtDA helped me to gain insight into my preferences, worries and questions

9 %

22 %

70 %

 

 The PtDA helped me in making a decision about medication

11 %

18 %

70 %

 

 The PtDA helped me in discussing my preferences, worries and questions with my rheumatologist

11 %

28 %

60 %

 

Total impact

   

3.8 ± 0.9

Perceived usefulness

 The PtDA in general was useful

7 %

5 %

88 %

 

 Reading the general information was useful

2 %

5 %

94 %

 

 The specific information about DMARDs was useful

4 %

3 %

94 %

 

 Comparing DMARDs was useful

4 %

8 %

89 %

 

 Making notes in the digital notebook was useful

22 %

51 %

28 %

 

 The exercises about preferences and worries were useful

11 %

29 %

59 %

 

 The list of frequently asked questions was useful

12 %

32 %

56 %

 

Total usefulness

   

4.0 ± 0.7

Perceived ease of use

 The website is easy to use

5 %

3 %

92 %

 

 The information is easy to understand

2 %

6 %

92 %

 

 The time the PtDA takes to finish is acceptable

5 %

5 %

90 %

 

 The structure of the website is logical

10 %

11 %

79 %

 

Total ease of use

   

4.5 ± 0.8

Attractiveness

 The colour of the website is pleasant

2 %

17 %

81 %

 

 The font on the website is pleasant

4 %

9 %

87 %

 

Total attractiveness

   

4.4 ± 0.9

Attitude towards future use

 I would use the PtDA again in the future

5 %

3 %

91 %

 

 I would recommend the PtDA to others

2 %

7 %

89 %

 

Total attitude

   

4.6 ± 0.9

Overall grade regarding the quality of the PtDA (range 0–10)

  

7.7 ± 0.9

  1. Percentages do not include missing cases. PtDA patient decision aid, DMARD disease modifying anti-rheumatic drug